New national data show five‑year lung‑cancer survival has climbed to about 30 percent. Triangle doctors point to immunotherapy, testing and screening as key drivers.

San Diego researchers warn federal grant cuts and delivery delays are already squeezing labs and slowing clinical trials, threatening local cancer breakthroughs.

Cursor is prepping Composer 2, a code-only model for long coding tasks, while fundraising chatter could push the SF startup’s valuation toward $50B.

Scripps Research chemists reworked fentanyl's core to keep pain relief while cutting respiratory danger in mice, offering a possible blueprint for safer opioids.

Meta will lay off roughly 331 Washington employees on March 20, concentrated in Redmond, Bellevue and Seattle as Reality Labs is pared back.

Lab scans of Bennu samples at Johnson Space Center reveal crack networks that explain why telescopes misread the asteroid’s heat signature and reshape remote sensing assumptions.

Jeff Bezos is reportedly pitching a $100 billion fund to acquire manufacturing firms and apply AI-driven automation linked to his Project Prometheus venture.

Mass General Brigham used AI to re‑read routine CTs and found thymus health may predict disease risk and responses to immunotherapy. The finding is promising but needs trial validation.

UPMC Hillman is rolling out PET‑guided radiotherapy, surface‑guided systems and radiopharmaceuticals across its network — clinicians report faster relief and fewer side effects for some patients.

Chicago-based Relativity filed confidentially for an IPO; Bloomberg told the Chicago Business Journal the offering could raise about $750M and value the company near $4B. The company says it has supported legal teams for about 25 years.

Goldman Sachs is investing $42.5M in Chicago‑based GeoWealth to extend its Series C and deepen a product partnership aimed at RIAs.

Daikin Park will add Evolv Gen2 scanners and the autonomous eXpedite bag scanner, promising faster entry lines and renewed privacy questions.

Salk researchers identified Med14, a Mediator protein that helps explain how GLP‑1 drugs can strengthen pancreatic beta cells and improve insulin release.